Relmada Therapeutics, Inc. (RLMD)
NASDAQ · Manufacturing · Pharmaceutical preparations
$3.83+$0.0200 (+0.52%) on the dayAs of the close; data may be delayed.
RLMD price, last 12 months
Key stats
- Previous close
- $3.81
- Open
- $3.81
- Day range
- $3.73 – $3.87
- 52-week range
- $1.53 – $8.00
- Volume
- 1.1M
- Avg volume (20 days)
- 1.3M
- Market cap
- $408.5M
Performance
1W−7.0%
1M−15.8%
3M−42.8%
6M−41.4%
YTD−20.7%
1Y+132.1%
vs S&P 500, 1Y+115.3 pts
Technicals and fundamentals
About Relmada Therapeutics, Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $408.5M